Oyster Point is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases.

Sectors
Healthcare
Life Sciences
First Invested
2019
Early
Company Status
NASDAQ: OYST
Acquired by Viatris
Associated Team
Ali Behbahani, MD